A first‐in‐human pharmacodynamic and pharmacokinetic study of a fully human anti‐glucagon receptor monoclonal antibody in normal healthy volunteers

AIMS: Glucagon receptor (GCGR) blockers are being investigated as potential therapeutics for type 1 and type 2 diabetes. Here we report the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of REGN1193, a fully human glucagon receptor blocking monoclonal antibody from a first‐in‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostic, Ana, King, Thomas Alexander, Yang, Feng, Chan, Kuo‐Chen, Yancopoulos, George D., Gromada, Jesper, Harp, Joyce B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813272/
https://www.ncbi.nlm.nih.gov/pubmed/28755409
http://dx.doi.org/10.1111/dom.13075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813272/
https://www.ncbi.nlm.nih.gov/pubmed/28755409
http://dx.doi.org/10.1111/dom.13075

Ejemplares similares